Semma to bring stem cell-derived islet therapies for diabetes to clinic in 2020 Semma Therapeutics Inc. (Cambridge, Mass.) plans to start Phase I testing in early 2020 of its stem cell-derived islets combined with immunosuppression in "brittle"
Read the full 369 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD